Glucagon-like peptide-1 (GLP-1) receptor agonists, including tirzepatide (Mounjaro), are widely used to manage type 2 diabetes mellitus (T2DM) and obesity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.